Genesis of the project

Classical chemotherapy is still, in addition to surgery, an essential tool in the hands of an oncologists to treat cancer patients. Nevertheless, its use is generally associated with strong side effects, often low efficacy, relapse, and very often with secondary drug resistance.  Current trends in anticancer therapeutics, therefore, seek to develop innovative therapeutic strategies.


Today  more and more pharmaceutical companies looking  for  innovative anti-cancer drug action directed to a defined molecular target tumor cell.  Clinical trials of new drugs are always preceded by extensive laboratory tests and preclinical, consisting of a preliminary assessment of activity of the compounds in vitro and then in vivo testing in animal models for the characteristics of pharmacology, pharmacokinetics and bioavailability and tolerability in animals.


Currently, the requirement of the European Union is to conduct these studies in laboratories with GLP standards.  At present, in Poland there is no certified laboratories wholesalejeans performing screening tests.  The creation of the Integrated Laboratory of Experimental NeoLek-Oncology and Innovative Technology opens the possibility of conducting such research in Poland, and will contribute to lower financial expenses, which pharmaceutical companies must devote to research.


Department of Experimental Oncology, which NeoLek derives from,  conducts research on substances with potential anticancer activity since 1969.  The Institute has extensive  experience in conducting screening studies and employs highly qualified scientists.  In addition,  the Institute of Immunology and Experimental Therapy, is Poland’s largest collection of cell lines.  The  collection brings together  over 160 reference cell line of  human and animal coming from reputable sources.  Collection has, among others sets of lines derived from human organ cancers, a line of human and murine vascular endothelial cells, genetically modified tumor and the tumor lines derived resistance to known and used in the clinic treating drugs.  This makes it possible to carry out screening of potential drugs for antiproliferative activity against a broad spectrum of tumor cells.


DAVIE, Fla. (AP) Jay Cutler has decided to postpone retirement for the chance to be Ryan Tannehill's replacement.Cutler agreed to terms Sunday on a contract with the Miami Dolphins, a person familiar with the situation said. The person confirmed the agreement Ryan Tannehill Jerseys to The Associated Press on condition of anonymity because the Dolphins weren't expected to announce the deal until Cutler signed the $10 million, one-year deal.Cutler will compete with Matt Moore for Cameron Wake Jerseys a starting job while Tannehill remains out with a left knee injury that could sideline him for the entire season.Dolphins coach Adam Gase was offensive coordinator for the Chicago Bears when Cutler had a career-best quarterback rating with them in 2015. Gase joined Miami in 2016, and Cutler parted with Chicago in March after eight seasons.Cutler, 34, drew little interest in the spring as a free agent, perhaps partly because Jarvis Landry Jerseys of his prickly personality and tendency for turnovers."I guess I know a different guy than what everybody else portrays," Gase said in May, when Cutler was hired by Fox as an analyst to work on its No. 2 NFL team.Tannehill, who missed the final four games of last season with two sprained ligaments in his knee, reinjured it a week into training camp Thursday. The damage is similar last year's injury, a personal familiar with Jay Ajayi Jerseys the diagnosis said, which has left the Dolphins consulting with specialists to determine whether surgery is the best option for Tannehill.He's expected to be sidelined a minimum of six weeks, but the deal with Cutler signals the Dolphins anticipate Tannehill will need a lengthier recovery.Cutler is 68-71 as a starter with a career quarterback rating of 85.7, 208 touchdown passes and 146 interceptions. Ndamukong Suh Jerseys Several NFL starting QBs are older, including New England's Tom Brady, who just turned 40.Moore turns 33 next week and has 28 starts in 10 seasons.